Irene:
1) Earnings:
Well, as I understand things, the legal expense is still a drain on the company. Then their shipments of fish supplement just now beginning. The animal supplement was held up for labelling, and the NSC-24 products are just now being introduced. No award yet on the Bollman Molecular issue. Meanwhile, growth of the company will involve continued red ink, I would think. So, if we break even as in last quarter, I would be happy. Now, if all of these issues get moved forward by Fall, we could show a dramatic turn-around by next February quarter.
MM Manipulation:
That last trade certainly caught my eye. Perhaps the timing is wrong for a dress-up of the price history. I hate to get paranoid about these MMs. No way we will ever know the truth of the situation, I suppose. Anyway, I will not be surprised with another loss for the quarter. We are moving lower along with the general market today. I still look for a $1.00 ask opportunity before long. Now that Art has arrived, perhaps he can make another assessment after this move downward. |
